AstraZeneca Nobel Medicine Initiative Launched in China
Tuesday, 1 November 2011
To mark the official launch of the AstraZeneca Nobel Medicine Initiative in China, Professor Barry Marshall, winner of the 2005 Nobel Prize for Physiology or Medicine for the discovery of Helicobacter pylori and its role in gastritis and peptic ulcer disease, shared his innovative approach to science in a series of lecturers to medical students, researchers, media and dignitaries in Beijing and Shanghai recently.
The aim of the global Initiative is to increase interest in the Nobel Prize awarded achievements within the fields of Physiology or Medicine among the general public, students and researchers and to explain the benefits of these discoveries worldwide. The Initiative in China comprised a series of high-profile events, including medical forums on innovation and lectures at universities. It is the first programme of this kind in the country and is intended to become an annual event.
Dr Steve Yang, Vice President, R&D Asia and Emerging Markets commented:
Hearing the lessons Professor Marshall learned, his current research and thoughts for the future, particularly around his Nobel Prize awarded work on the bacterium Helicobacter pylori was an inspiration for everyone who was lucky enough to be present. AstraZeneca is proud to inspire students and scientists to aim higher in their pursuit of innovation and increasing public awareness about the important role of medical innovation and research.
President of AstraZeneca China, Mark Mallon, who introduced Prof Marshall’s lecture in Shanghai said, “It was an honour to have someone of Prof Marshall’s calibre participate in the inaugural AstraZeneca Nobel Medicine Initiative event here in China.”
In addition to Professor Marshall’s speech Professor You Suning, Director and Chief Editor, Chinese Medical Association Publishing House, shared his views on how to communicate the latest medical research developments to Chinese and global audiences while Dr. Yang spoke about the importance of innovation for pharmaceutical companies.